

1

2

Maternal obesity and metabolic disorders associate with

3

congenital heart defects in the offspring:

4

a systematic review

5

6 Gitte Hedermann\*<sup>1</sup>, Paula L Hedley<sup>1</sup>, Ida N Thagaard<sup>1,2</sup>, Lone Krebs<sup>3,4</sup>, Charlotte Kvist Ekelund<sup>4,5</sup>, Thorkild IA

7 Sørensen<sup>6,7</sup>, Michael Christiansen<sup>1,8</sup>

8

9 <sup>1</sup> Department for Congenital Disorders, Danish National Biobank and Biomarkers, Statens Serum Institut, Copenhagen,

10 Denmark

11 <sup>2</sup> Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

12 <sup>3</sup> Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Amager and Hvidovre Hospital,

13 Copenhagen, Denmark

14 <sup>4</sup> Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

15 <sup>5</sup> Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen,

16 Denmark

17 <sup>6</sup> Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark

18 <sup>7</sup> The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences,

19 University of Copenhagen, Copenhagen, Denmark

20 <sup>8</sup> Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

21    Keywords:                            Obesity; diabetes mellitus; hypertension; congenital heart defects

22    Running title:                        Maternal metabolic disorders and foetal CHDs

23    Acknowledgements:                Thank you to the researchers who readily provided supplementary information. This

24    research has been conducted using the Danish National Biobank resource supported

25    by the Novo Nordisk Foundation.

26    An earlier version of the article is available at a preprint server, MedRxiv (DOI:

27    <https://doi.org/10.1101/2020.06.25.20140186>).

28    Funding information:                This study was supported by The Danish Children Heart Foundation (18-R109-A5193-

29    26043), The A.P. Moller Foundation (19-L-0096), and Aase and Ejnar Danielsen's

30    Foundation (19-10-0493). The funders had no role in study design, data collection and

31    analysis, decision to publish, or preparation of the manuscript.

32    Corresponding author\*:            Department for Congenital Disorders

33    Danish National Biobank and Biomarkers

34    Statens Serum Institut

35    Artillerivej 5

36    2300 Copenhagen

37    Denmark

38    [gihc@ssi.dk](mailto:gihc@ssi.dk)

39    Conflict of interests:                All authors have completed the ICMJE uniform disclosure form at

40    [http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declared no financial relationships with

41    any organizations that might have an interest in the submitted work in the previous

42    three years, and no other relationships or activities that could appear to have

43    influenced the submitted work.

## 44 **Summary**

45 Congenital heart defects (CHDs) are the most common congenital malformations and affect neonatal mortality and  
46 morbidity. The aetiology of CHDs is complex. Large cohort studies have reported an association between higher risk of  
47 CHDs in the offspring and individual maternal metabolic disorders such as obesity, diabetes, hypertension, and  
48 preeclampsia, all conditions that can be related to insulin resistance or hyperglycaemia and possibly metabolic  
49 syndrome (MetS). The aim of this review is to evaluate the existing evidence on the association between maternal  
50 metabolic disorders, defined as obesity, diabetes, hypertension, preeclampsia, dyslipidaemia, and MetS, or  
51 combinations thereof and CHDs overall as well as by subtype in the offspring. A literature search of PubMed and  
52 Embase databases identified 2,076 studies, 30 qualified for inclusion. All but one study investigated the individual  
53 metabolic disorders and their association with CHDs. Some disorders (obesity, gestational diabetes, and hypertension)  
54 increased risk of CHDs marginally whereas pre-gestational diabetes and early-onset preeclampsia were strongly  
55 associated with CHDs, without consistent differences between CHD subtypes. Future studies of the role of aberrations  
56 of the glucose-insulin homeostasis in the common aetiology and mechanisms of metabolic disorders, present during  
57 pregnancy, and their association with CHDs as well as subtypes of CHDs are needed.

58

59 Abbreviations:

60 CHDs, congenital heart defects; MetS, metabolic syndrome; PE, preeclampsia; BMI, body mass index; GDM,  
61 gestational diabetes; DM2, diabetes type 2; DM1, diabetes type 1; ICD-10, International Classification of Diseases, 10<sup>th</sup>  
62 revision; OR, odds ratio; RR, risk ratio; PR, prevalence ratio; CI, 95% confidence interval; PGDM, pre-gestational  
63 diabetes.

## 64 **1. Introduction**

65 Congenital heart defects (CHDs) are structural malformations of the heart and/or the great intrathoracic vessels. They  
66 are the most frequent congenital malformation<sup>1</sup> and prevalence is estimated to be around 8-10 per 1,000 live births  
67 worldwide.<sup>1-4</sup> The most critical and severe defects, the major CHDs, (1-2 per 1,000 live births) have a serious impact  
68 on neonatal mortality and morbidity, and frequently result in neonatal heart failure or circulatory collapse requiring  
69 acute surgery.<sup>4</sup> However, other types of CHDs, like bicuspid aortic valve and transient septal heart defects, are far  
70 more frequent but of limited clinical significance.

71 The aetiology of CHDs is complex and poorly understood. An identifiable underlying cause (genetic and/or  
72 environmental) is present in 20-30% of CHDs.<sup>5</sup> Thus, 8-10% of CHDs can be attributed to chromosomal aberrations  
73 (e.g., DiGeorge syndrome, Down syndrome, Turner syndrome, etc.)<sup>5,6</sup>; while 5-15% may be the result of single-  
74 nucleotide or pathogenic copy number variants.<sup>5,7</sup> Additionally, viral infections in pregnancy (e.g., rubella), as well as  
75 exposure to certain teratogenic substances (e.g., alcohol or antiepileptic drugs)<sup>8</sup> may cause CHDs if the foetus is  
76 exposed at a critical point in development.

77 The normal pregnancy is an adaptive interplay between the maternal metabolism and foetal development.  
78 Differentiation of cardiac tissues begins in the third week of gestation, and by week eight, the foetal heart has  
79 undergone major changes, and will resemble the postnatal heart in structure and function.<sup>9</sup> Thus, the maternal-foetal  
80 interaction in the first two months of pregnancy is likely to be the most relevant window in time for a causative  
81 relation between maternal metabolism and CHDs. In first trimester, the foetus does not have the ability to secrete  
82 insulin, which may result in foetal hyperglycaemia in the event of relative maternal insulin resistance.<sup>10</sup> Animal models  
83 have shown that in embryos of chicks and rodents, exogenous glucose may cause a variety of malformations.<sup>11,12</sup> The  
84 significance of foetal hyperglycaemia has not been demonstrated in humans, but increasingly worse glycaemic control  
85 around conception in women with diabetes type 1 (DM1) has recently been reported to be associated with a  
86 progressively increased risk of CHDs in the offspring.<sup>13</sup>

87 Large cohort studies from Scandinavia and North America have reported an association between increased risk of  
88 CHDs and maternal metabolic disorders such as obesity,<sup>14,15</sup> diabetes,<sup>16-18</sup> hypertension,<sup>19,20</sup> and preeclampsia (PE).<sup>21,22</sup>

89 All these metabolic disorders can be associated with hyperglycaemia and underlying insulin resistance, and thereby  
90 through the metabolic syndrome (MetS).<sup>23,24</sup>  
91 MetS includes a cluster of metabolic disorders in combination, usually any three of the following: abdominal obesity,  
92 insulin resistance, hypertension, and dyslipidaemia.<sup>23,25</sup> It is commonly reported to be a risk factor for diabetes type 2  
93 (DM2) and cardiovascular disease in a non-pregnant population. Only a single multi-centre study from Australia, New  
94 Zealand and United Kingdom has assessed MetS in pregnant women and reported an incidence of 12.3% at 15 weeks'  
95 gestation<sup>26</sup> using the International Diabetes Federation criteria.<sup>25</sup> It is plausible that obesity, diabetes, hypertension,  
96 PE and dyslipidaemia as individual conditions, or more likely in combination, during pregnancy are expressions of  
97 insulin resistance and MetS.<sup>23,24</sup> Combinations of several maternal metabolic disorders in the same pregnancy (defined  
98 as obesity, diabetes, hypertension, PE, and dyslipidaemia), all related to MetS, are likely to be associated with higher  
99 risk of CHDs in the offspring as compared to women with a single disorder.

100 The aim of this systematic review is to evaluate the literature of associations between maternal metabolic disorders  
101 (obesity, diabetes, hypertension, PE, dyslipidaemia, or MetS) or combinations thereof and CHDs in the offspring. The  
102 relation with overall occurrence of CHDs as well as CHDs broken down into individual subtypes. Since these maternal  
103 metabolic disorders likely persist over time, they may be relevant for the risk of CHDs in subsequent pregnancies. On  
104 this background, we will point to gaps in current knowledge and make recommendations for future research possibly  
105 paving the way to improved prevention of CHDs.

106

## 107 **2. Methods**

### 108 **2.1 Search strategy**

109 A systematic literature search of papers published between January 1, 1990 and October 6, 2019 was conducted using  
110 PubMed and Embase. MetS was initially described by G.M. Reaven in 1988 as an "insulin resistance syndrome",<sup>27</sup> and  
111 the literature search was limited to publications focussing on its role in CHDs. The search strategy used keywords that  
112 combined CHDs and pregnancies with maternal metabolic disorders (obesity, diabetes, hypertension, PE,  
113 dyslipidaemia and/or MetS). Although DM1 is not a part of the MetS, it was included in the review as a metabolic

114 disorder because the associated hyperglycaemia is known to be associated with CHDs. More details about the  
115 literature search can be found in Table S1. Subsequently, reference lists from the individual papers were reviewed for  
116 additional relevant studies.

117

## 118 2.2 Exposures, outcomes and definitions

119 The exposures of interest were maternal overweight and obesity, diabetes (DM1, DM2 or gestational diabetes  
120 (GDM)), hypertension, PE, dyslipidaemia, and/or MetS during pregnancy. Maternal body mass index (BMI) (weight in  
121 kilograms divided by the square of the height in meters ( $\text{kg}/\text{m}^2$ )) was defined as pre-pregnancy or early-pregnancy BMI  
122 measured in first trimester. The outcome of interest was CHDs defined as structural malformations of the heart  
123 chambers, heart valves, great arteries and septal defects, corresponding to DQ20-26 in the World Health Organization  
124 International Classification of Diseases (ICD-10) or diagnoses referable to these. The CHD diagnoses are described as  
125 “any CHDs” for the whole group of heart defects (only including studies that explicitly listed their definition thereof),  
126 “major CHDs” for a group of the most critical and severe CHD diagnoses or as CHD subtypes in relation to the maternal  
127 disorders. Studies could include both singleton and multiple births.

128

## 129 2.3 Eligibility criteria

130 Two different authors (GH, PLH and/or INT) screened all titles and abstracts individually. Studies were initially eligible  
131 if they met the following criteria: 1. Studies were published in English; 2. Studies were case-control or cohort studies;  
132 3. The exposures of interest were maternal overweight or obesity, hypertension, PE, diabetes, dyslipidaemia, and/or  
133 MetS; and 4. The outcome of interest was CHDs in the offspring.

134

## 135 2.4 Quality assessment

136 One author (GH) conducted the study selection and quality assessment based on a full-text review. Any doubts were  
137 resolved by discussion with at least one co-author. The Newcastle-Ottawa Scale was used to assess the quality of

138 eligible studies.<sup>28</sup> Using this tool (Table S2), each study was judged on three categories: 1. selection of cohorts or cases  
139 and controls; 2. comparability of cohorts or cases and controls on the basis of the design or analysis; and 3.  
140 ascertainment of outcome or exposure. Highest quality studies could be awarded nine stars. If a study received seven  
141 or more stars (Table S3), it was considered of high methodological quality and included in the review.<sup>28</sup>

142 Data was extracted to figures without processing results. Results are presented as odds ratios (OR), risk ratios (RR) or  
143 prevalence ratios (PR) with 95% confidence interval (CI). Results are presented adjusted (aOR/aRR/aPR) for pertinent  
144 possible confounding factors, if accessible.

145

### 146 **3. Results**

#### 147 **3.1 Study identification and selection**

148 The selection of studies is described in Figure 1. In the event of multiple publications using the same data, we included  
149 the study that provided the most comprehensive information. A total of 30 publications were included in the review  
150 (Table 1 and Table S3). Among these, 15 dealt with maternal overweight or obesity,<sup>14,15,19,29-40</sup> nine dealt with pre-  
151 gestational diabetes (PGDM),<sup>16-18,40-45</sup> four dealt with DM1,<sup>13,19,46,47</sup> two dealt with DM2,<sup>19,46</sup> seven dealt with GDM,<sup>16-  
152 18,39,40,44,47</sup> four dealt with hypertension,<sup>19,20,41,46</sup> three dealt with PE,<sup>21,22,48</sup> and none were about dyslipidaemia or MetS  
153 (as a diagnostic category). Except for the combination of PGDM and GDM, five studies investigated more than one  
154 maternal metabolic disorder (but not in combination),<sup>19,39-41,46</sup> and one study assessed a combination of two  
155 conditions (obesity and GDM) and the risk of CHDs.<sup>31</sup>

156

#### 157 **3.2 Study characteristics**

158 The 30 included studies consisted of 17 cohort studies and 13 case-control studies. Characteristics of the 30 studies  
159 are presented in Table 1 and Table S3. Two examined populations of non-European descent (Taiwan and China).<sup>39,46</sup>  
160 Half of the studies reported results from livebirths only; eight studies had populations including both singleton and  
161 multiple births; and nine studies did not state whether they included only singleton or multiple births. Associations

162 between maternal metabolic disorders and CHDs are illustrated in Figure 2 (any CHDs) and Figures S1-S20 (CHD  
163 subtypes). All 30 studies were assessed using the Newcastle-Ottawa Scale and were required to be of high  
164 methodological quality (Table S2 and Table S3). Study designs were heterogeneous, particularly regarding the  
165 definition and categorization of the maternal metabolic disorders.

166

### 167 3.3 Maternal overweight or obesity and CHDs in the offspring

168 Several studies have investigated the association between maternal overweight or obesity and any  
169 CHDs.<sup>14,15,19,31,33,37,49</sup> In Figure 2, four out of seven studies found a significant association between maternal obesity  
170 (BMI  $\geq 30$  kg/m<sup>2</sup>) and any CHDs. Three of them reported higher risk estimates for any CHDs with higher maternal BMI:  
171 RR 1.07 (BMI 25-29.9 kg/m<sup>2</sup>) and RR 1.60 (BMI  $\geq 40$  kg/m<sup>2</sup>);<sup>14</sup> aOR 1.15 (BMI 25-29.9 kg/m<sup>2</sup>) and aOR 1.34 (BMI  $\geq 40$   
172 kg/m<sup>2</sup>);<sup>15</sup> and aOR 1.16 (BMI 25-29.9 kg/m<sup>2</sup>) and aOR 1.31 (BMI  $\geq 35$  kg/m<sup>2</sup>).<sup>31</sup> The fourth study only reported an  
173 association between maternal obesity diagnosed as ICD-10 codes and any CHDs, and did not assess the risk in relation  
174 to BMI categories.<sup>19</sup> Three studies found no significant association between any CHDs in the offspring and maternal  
175 overweight or obesity.<sup>33,37,49</sup>

176 Most studies investigated specific CHD subtypes in relation to maternal BMI, these results are presented for maternal  
177 obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) in Figures S1-S20. Some studies found significant associations between obesity and 13 CHD  
178 subtypes, however, other studies did not find a significant association.

179

### 180 3.4 Maternal pre-gestational diabetes and CHDs in the offspring

181 Most studies defined PGDM as either DM1 or DM2 (Table S3). Only four studies assessed DM1 or DM2  
182 individually.<sup>13,19,46,47</sup> Seven studies found a strong significant association with any CHDs (Figure 2), irrespective of the  
183 type of diabetes investigated, PGDM,<sup>16-18,44</sup> DM1,<sup>13,19,46</sup> or DM2.<sup>19,46</sup>  
184 Two studies presented associations between PGDM and major CHDs, but they defined major CHDs differently: Leirgul  
185 *et al.* found an association between PGDM and major CHDs (aRR 3.34, CI 2.48-4.49),<sup>18</sup> and Chou *et al.* found an

186 association between DM2 and major CHDs (aOR 2.80, CI 2.04-3.85), but did not find a significant association between  
187 DM1 and major CHDs (aOR 0.73, 0.10–5.32).<sup>46</sup>

188 Several studies have investigated the relationship between PGDM, DM1 or DM2 and specific CHD diagnoses<sup>16–19,40–45,47</sup>  
189 and in many cases found a strong significant association (Figures S1-S20).

190

### 191 3.5 Maternal gestational diabetes and CHDs in the offspring

192 Five studies reported an association between GDM and any CHDs,<sup>16–18,39,44</sup> but only the results from four of them are  
193 shown in Figure 2. The last study by Øyen *et al.* found an association between any CHDs and GDM diagnosed in the  
194 third trimester (aRR 1.36; CI 1.07-1.69), but did not find a significant association between any CHDs and GDM  
195 diagnosed in the second trimester.<sup>16</sup> Five studies reported a weak association between GDM and some subtypes of  
196 CHDs (Figures S1-S20).

197

### 198 3.6 Maternal chronic hypertension and CHDs in the offspring

199 Two large cohort studies from Canada and Taiwan reported a significant association between maternal pre-existing  
200 chronic hypertension and any CHDs (Figure 2).<sup>19,46</sup> Two studies assessed the association between subtypes of CHDs  
201 and chronic hypertension,<sup>19,41</sup> (Figures S1-S20), but associations were inconsistent. None of the three studies  
202 mentioned reported on potential antihypertensive drug use by the mothers. An American case-control study with  
203 10,625 cases with CHDs found a significant association between untreated hypertension and any CHDs (Figure 2) as  
204 well as for five subtypes of CHDs (Figures S1-S20).<sup>20</sup>

205

### 206 3.7 Maternal preeclampsia or gestational hypertension and CHDs in the offspring

207 Three studies investigated associations between PE and any CHDs or major CHDs. Although the definition of PE varied  
208 among the studies, all studies defined early-onset PE as diagnosed before gestational week 34, and the association

209 with any CHDs can be seen in Figure 2. Pregnancies with PE were associated with any CHDs (PR 1.57, CI 1.48-1.67),<sup>22</sup>  
210 and early-onset PE was associated with major CHDs (aRR 2.7, CI 1.3-5.6,<sup>48</sup> and aPR 3.64, CI 2.17-6.10<sup>22</sup>), all compared  
211 to normotensive pregnancies.

212 Weaker associations, between PE and any CHDs, were reported when PE was diagnosed later in pregnancy: PE with  
213 delivery at 34 to 36 weeks (OR 2.82, CI 2.38-3.34);<sup>21</sup> PE at term (OR 1.16, CI 1.06-1.27);<sup>21</sup> and late-onset PE (> 34  
214 weeks' gestation) (aPR 1.14, CI 1.06-1.23).<sup>22</sup> Furthermore, Boyd et al. did not find an association between gestational  
215 hypertension and any CHDs.<sup>21</sup> The studies also assessed subtypes of CHDs and their association with early-onset PE,  
216 which are illustrated in Figures S1-S20, especially atrioventricular septal defects (Figure S9) and atrial septal defects  
217 (Figure S19) were strongly associated with early-onset PE.

218

### 219 3.8 Risk of CHDs in the offspring in subsequent pregnancies

220 Two studies assessed PE and CHDs, and potential risks of both in subsequent pregnancies.<sup>21,48</sup> While, Brodwall et al.  
221 did not find an association between PE and CHDs across pregnancies,<sup>48</sup> Boyd et al. reported a much higher risk of  
222 having a child with CHDs in subsequent pregnancies after a pregnancy with PE and delivery before 34 weeks' gestation  
223 (OR 7.91, CI 6.06-10.3). Boyd et al. also found an association between a previous pregnancy with a child with CHDs  
224 and increased risk of PE with delivery before 34 weeks' gestation in subsequent pregnancies (OR 2.37; CI 1.68-3.34).<sup>21</sup>  
225 Studies on the other maternal metabolic disorders did not comprise an analysis of risks in subsequent pregnancies.

226

### 227 3.9 Combination of maternal obesity and gestational diabetes and CHDs in the offspring

228 Only one study comprised an assessment of the risk associated with pregnancies affected by two maternal metabolic  
229 conditions. Gilboa et al. reported a possible additive effect of the combination of maternal obesity (BMI  $\geq 30$  kg/m<sup>2</sup>)  
230 and GDM and the risk of any CHDs compared to only obesity (aOR 1.82 vs. 1.31).<sup>31</sup> The relation between the  
231 combination of maternal obesity and GDM and subtypes of CHDs are reported in Figures S1-S20 showing a significant  
232 association for six subtypes of CHDs.

233

## 234 **4. Discussion**

### 235 4.1 Main findings

236 The associations between any CHDs and maternal metabolic disorders fall in three groups: A. chronic hypertension,  
237 GDM, and obesity with OR/RR/PR of 1.2-1.9; B. PGDM with OR/RR/PR around 3-4; and C. early-onset PE with  
238 OR/RR/PR of 5-7. Thus, for the most prevalent maternal conditions, the associated risks of CHDs are only marginally  
239 elevated. Although maternal obesity is associated with higher risk of GDM, DM2, hypertension, PE, and  
240 dyslipidaemia,<sup>50</sup> no studies assessing the association between CHDs in the offspring and the combination of all  
241 maternal metabolic disorders were identified, and only one study dealt with the combination of two maternal  
242 metabolic conditions (obesity and GDM) as risk factor for CHDs in the offspring.<sup>31</sup> All other studies investigated the  
243 individual metabolic disorders and their association with CHDs, and there were no eligible studies on dyslipidaemia.  
244 Overall, those studies found a significant association between any CHDs and obesity, PGDM, GDM, hypertension, or  
245 early-onset PE, respectively (Figure 2). Contradictory evidence of associations with subtypes of CHDs were noted for  
246 most maternal conditions, with the exception of early-onset PE, which was strongly associated with both  
247 atrioventricular septal defects (Figure S9) and atrial septal defects (Figure S19); and PGDM which was strongly  
248 associated with most subtypes (Figures S1-S20).  
249 Early-onset PE was strongly associated with a higher risk of having a child with CHD in subsequent pregnancies, studies  
250 on the other maternal metabolic disorders did not approach risks in subsequent pregnancies.

251

### 252 4.2 Aetiological considerations and possible prevention of CHDs

#### 253 4.2.1 Relation between maternal metabolic disorders and foetal heart development

254 There is a clear pathophysiological connection between maternal insulin resistance and foetal CHDs, with glucose-  
255 mediated mechanisms of CHD involving multiple developmental pathways:<sup>51</sup> comprise left-right patterning,<sup>52</sup>  
256 alterations in neural crest cells migration and formation,<sup>53,54</sup> increased apoptosis<sup>55,56</sup> as well as changes in nitric oxide  
257 signalling,<sup>57</sup> and impaired autophagy.<sup>58</sup> All these mechanisms may cause or modify the development of CHDs. The  
258 investigated maternal metabolic disorders (obesity, diabetes, hypertension, preeclampsia, dyslipidaemia, and Mets)

259 are all linked to insulin resistance and/or hyperglycaemia.<sup>24,59</sup> The finding of the same association for these conditions  
260 as for DM1<sup>16</sup> justifies a particular focus on the role of aberrations in the glucose-insulin homeostasis. Obesity, DM1,  
261 DM2, chronic hypertension, and dyslipidaemia are present prior to conception and therefore affect maternal  
262 metabolism and foetal development during the essential first two months of pregnancy. However, PE and GDM are  
263 per definition not diagnosed before mid-pregnancy,<sup>60,61</sup> but it is likely that subclinical metabolic alterations emerge at  
264 a much earlier stage. It can be challenging to distinguish GDM from PGDM since most women are not screened for  
265 diabetes before pregnancy, and up to 50% of women diagnosed with GDM develop DM2 within five years after giving  
266 birth.<sup>62</sup> So it is plausible that many women with GDM might already be insulin resistant without it being detectable in  
267 first trimester. This is particularly challenging because fasting and postprandial glucose concentrations are normally  
268 lower in the early part of pregnancy (e.g., first trimester and first half of second trimester) than in normal, non-  
269 pregnant women.<sup>61</sup> Insulin resistance is more pronounced early in pregnancies with PE compared to pregnancies  
270 without PE.<sup>24,63</sup> In first trimester pregnancies that later develop PE are characterised by changes in IGF-axis markers,  
271 e.g. PAPP-A, and ProMBP,<sup>64,65</sup> placental proteins,<sup>66</sup> and adipokines, e.g. leptin and adiponectin,<sup>67,68</sup> indicating that the  
272 clinical presentation of PE is preceded by a foeto-maternal dyscrine condition. The fact that the nutritional status of  
273 the foetus influences the risk of cardiovascular disease in adulthood (Barker Hypothesis)<sup>69</sup> - also indicates that  
274 placental function may play a role in the aetiology of foetal malformations. There is a need to identify particular  
275 pathways where perturbations, especially in the glucose-insulin axis, cause specific malformations, but such studies  
276 will have to be large as some of the malformations are fairly rare and the molecular aetiology likely heterogeneous.

277

#### 278 4.2.2 Possible teratogenic effect of medication

279 Women with chronic hypertension or DM1 will most likely be undergoing medical treatment as well as some women  
280 with DM2 will be treated with antidiabetic drugs. Some of these drugs might have a teratogenic effect and by not  
281 taking them into considerations in the studies, they could influence the estimates of association. It is thus important  
282 to distinguish between the effects of the drugs and the conditions proper. Insulin is not believed to be teratogenic,<sup>70</sup>  
283 suggesting that the focus should be on the insulin resistance and the glucose levels. Observational studies suggest that  
284 exposure to either metformin or beta-blockers during pregnancy may actually increase the risk of certain types of

285 CHDs in the foetus.<sup>20,71</sup> A meta-analysis by Ramakrishnan et al. observed an association between untreated  
286 hypertension and CHDs, which suggests that the association between hypertension and CHDs is not simply due to  
287 teratogenic effects of medication alone, but the effect was larger for treated hypertension.<sup>72</sup> Thus, antihypertensive  
288 medications may lead to an additional increase in risk, but it might also just indicate a more severe disease in the  
289 mother.

290

#### 291 4.2.3 Prevention of CHDs in the offspring

292 It is very well-established that maternal obesity is associated with marginally increased risk of CHDs, and two meta-  
293 analyses reported a dose-response effect on risk of CHDs with increasing BMI.<sup>73,74</sup> But an increase of 20-40% of a very  
294 small risk in general may not be clinically significant. Particularly as it has not yet been shown that weight reduction  
295 normalizes the risk and a study showing such an effect would be complicated and difficult to perform. Future studies  
296 investigating the prevalence of CHDs in obese pregnant women could compare women who had undergone bariatric  
297 surgery with a control group as well as risk in pregnancies before and after the surgery as it has been done in studies  
298 on birth weight and obesity in childhood.<sup>75,76</sup> The Swedish cohort study of 1.2 million pregnant women with DM1  
299 showed that poor glycaemic control around conception was associated with a progressively higher risk of CHDs in the  
300 offspring.<sup>13</sup> PGDM and early-onset PE have a strong association with CHDs, however, the clinical significance of  
301 preventive measures has not been established.

302

#### 303 4.3 Heterogeneity in studies

304 Comparison of results from different studies in this review was hampered by heterogeneity. This is due to several  
305 factors: 1. Case-control studies provide estimates of risk that may be less valid and reliable than prospective,  
306 population-based cohort studies for estimating occurrence of CHDs—i.e., for some subtypes of CHDs, the cohort  
307 studies find a significant association while the results from the case-control studies are insignificant. 2. The studies  
308 assessing maternal obesity and CHDs often excluded pregnancies with PGDM, whereas others did not and are  
309 therefore difficult to compare; studies on obesity usually also divided maternal BMI into categories that distinguished

310 them from a direct comparison with another study. 3. Diagnostic criteria for PGDM and GDM were not always  
311 explained. 4. Not all studies include stillbirths and terminated pregnancies, which could skew the results, i.e., the risk  
312 of CHDs in live born offspring of women with obesity relative to women without obesity might be overestimated,  
313 since it is well-known that congenital malformations are more difficult to detect by prenatal ultrasound in these  
314 women and they are therefore not necessarily given the possibility to terminate the pregnancy in case of a severe  
315 malformation.<sup>77</sup> 5. Studies on both singleton and multiple births without distinguishing between them may add to the  
316 heterogeneity because the risk of CHDs is higher in multiple birth.<sup>78</sup>  
317 We presented adjusted risks and compared them although the studies did not all adjust for the same confounders.  
318 Many studies adjust for maternal age, parity and year of birth, while others also adjust for race/ethnicity, education,  
319 smoking, marital status etc. Even though not always available, we could have presented crude risks, however, we  
320 believe that the adjusted risks represent the best possible estimate since results otherwise would have been known to  
321 be biased.

322

#### 323 4.6 Significance of genetic aetiology

324 The aetiology of CHD is complex and the important breakthroughs in next generation sequencing of whole genomes  
325 as well as implementation of chromosomal micro arrays have as of now led to the identification of a strong genetic  
326 component in 15-20% of CHD cases.<sup>5</sup> The genetic aetiology ranges from chromosomal disorders over micro-deletions  
327 to copy number variants and single-gene disorders. Many of the genetic causes of CHDs are characterized by extensive  
328 phenotypic variability and a broad spectrum of comorbidities.<sup>5</sup> Thus, some cases of e.g. Williams syndrome<sup>79</sup> as well as  
329 Bardet-Biedl syndrome<sup>80</sup> exhibit malformations in combinations with obesity, DM2, and hypertension. In cases where  
330 the mother carries genetic variants that cause or pre-dispose to such conditions, the association between CHDs and  
331 maternal metabolic disorders might be one of common aetiology (horizontal pleiotropy) rather than one of a causal  
332 relation between maternal conditions and the development of CHDs (vertical pleiotropy). With further advances in  
333 genetic characterization of CHDs, one might see a more detailed understanding of the extent of comorbidities in CHD-  
334 associated genetic disorders. This phenomenon might bias the association analysis.

335

#### 336 4.7 Strengths and limitations

337 The strength of this review is that we have selected only high-quality, original research studies from a systematic  
338 literature search. However, we have limited our selection of studies to those published in English and from 1990 and  
339 after, which may have excluded a number of high-quality studies, which were published in another language or before  
340 1990. However, the screening of the references of the articles included did not reveal relevant studies published  
341 before 1990. Furthermore, our review did not include meta-analyses as prescribed by PRISMA since we found the data  
342 too heterogeneous to summarize in a meta-analysis.

343

#### 344 4.8 Perspectives

345 The global prevalence of CHDs has increased by 10% every five years between 1970 and 2017, which probably is due  
346 to increased detection of milder lesions.<sup>2</sup> The incidence of MetS often parallels the incidence of obesity, which has  
347 nearly tripled worldwide since 1975,<sup>81</sup> and Centers for Disease Control and Prevention estimated that 40% of women  
348 aged 20-39 years old in the United States had a BMI  $\geq 30$  kg/m<sup>2</sup> in 2017-2018.<sup>82</sup> Maternal obesity and dyslipidaemia  
349 increases the risk of developing both PE and GDM,<sup>83,84</sup> GDM closely associated with risk of DM2, PE increases the risk  
350 of future chronic hypertension,<sup>85</sup> and studies indicate that women with PE have increased risk of insulin resistance  
351 later in life.<sup>86</sup> So, the maternal metabolic disorders might be related to later MetS (except for DM1), and all  
352 components are associated with CHDs in offspring – either individually or with an additive effect. Our analysis shows  
353 that there is a remarkable lack of knowledge on several aspects of the link between maternal metabolic disorders and  
354 CHDs in the offspring. Large population-based studies are needed to identify possible synergistic effects. Indeed, the  
355 combination may have a greater impact than each individual factor and result in amplified risk of CHDs – also taking  
356 into consideration at what time the maternal metabolic disorder develops in relationship to the development of the  
357 foetal heart. Furthermore, such studies should be ethnically inclusive, and also include women of different socio-  
358 economic status. There is also a need for more detailed studies of the molecular mechanisms of CHDs, especially  
359 regarding the possibly common underlying pathophysiological mechanisms, insulin resistance and glucose-insulin  
360 homeostasis in particular, and their genomic basis. A combination of such studies in carefully investigated cohorts and  
361 the use of electronic health records in a population-wide biobank setting could bring relevant knowledge on

362 mechanisms that might pave the way to preventive approaches to CHDs. Furthermore, it is important to examine  
363 whether a modification of a pre-existing condition influences risks for CHDs.

364

## 365 **5. Conclusion**

366 CHDs are the most common malformations and a major cause of morbidity and mortality in childhood. Although the  
367 aetiology is complex, it is important to identify risk factors in order to pave the way for targeted prevention of CHDs.  
368 Our review shows that there is a well-established association, albeit to a varying extent, between individual maternal  
369 metabolic disorders such as obesity, diabetes, hypertension, and PE with increased risk of CHDs in the child. Since  
370 occurrence of MetS is rapidly increasing, there is a need for such studies. Secondly, there is a need for large studies  
371 based on genetically characterized CHD cases, where the association with MetS could be an expression of comorbidity  
372 involving both CHDs and maternal metabolic disorders implying aberrations of the glucose-insulin homeostasis.  
373 Thirdly, there is a need for studies covering populations other than those of European and Asian descent, particularly  
374 as the prevalence of MetS and its different manifestations vary widely around the globe. Such studies may result in  
375 the identification of subgroups of women, in whom MetS might be of particularly importance as a risk factor. Finally, it  
376 is important to examine whether preventive actions against pre-pregnancy maternal metabolic disorders influences  
377 the risk of CHDs.

## 378 **References**

- 379 1. Dolk H, Loane M, Garne E, European Surveillance of Congenital Anomalies (EUROCAT) Working Group.  
380 Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. *Circulation*.  
381 2011;123(8):841-849.
- 382 2. Liu Y, Chen S, Zühlke L, et al. Global birth prevalence of congenital heart defects 1970–2017: updated systematic  
383 review and meta-analysis of 260 studies. *Int J Epidemiol*. 2019;48(2):455-463.
- 384 3. van der Linde D, Konings EEM, Slager MA, et al. Birth Prevalence of Congenital Heart Disease Worldwide. *J Am*  
385 *Coll Cardiol*. 2011;58(21):2241-2247.
- 386 4. Lytzen R, Vejstrup N, Bjerre J, et al. Live-Born Major Congenital Heart Disease in Denmark: Incidence, Detection  
387 Rate, and Termination of Pregnancy Rate From 1996 to 2013. *JAMA Cardiol*. 2018;3(9):829-837.
- 388 5. Pierpont ME, Brueckner M, Chung WK, et al. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific  
389 Statement From the American Heart Association. *Circulation*. 2018;138(21):e653-e711.
- 390 6. van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJM. The changing epidemiology of  
391 congenital heart disease. *Nat Rev Cardiol*. 2011;8(1):50-60.
- 392 7. Jin SC, Homsy J, Zaidi S, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart  
393 disease probands. *Nat Genet*. 2017;49(11):1593-1601.
- 394 8. Hoffman JIE. Epidemiology of congenital heart disease: etiology, pathogenesis, and incidence. In: Yagel S,  
395 Silverman NH, Gembruch U, eds. *Fetal Cardiology: Embryology, Genetics, Physiology, Echocardiographic*  
396 *Evaluation, Diagnosis and Perinatal Management of Cardiac Diseases*. 2<sup>nd</sup> ed. Taylor & Francis; 2009: 101-110.
- 397 9. Wenink ACG. Cardiovascular development. In: Yagel S, Silverman NH, Gembruch U, eds. *Fetal Cardiology:*  
398 *Embryology, Genetics, Physiology, Echocardiographic Evaluation, Diagnosis and Perinatal Management of*  
399 *Cardiac Diseases*. 2<sup>nd</sup> ed. Taylor & Francis; 2009:1-8.

- 400 10. Rorsman P, Arkhammar P, Bokvist K, et al. Failure of glucose to elicit a normal secretory response in fetal  
401 pancreatic beta cells results from glucose insensitivity of the ATP-regulated K<sup>+</sup> channels. *Proc Natl Acad Sci U S*  
402 *A*. 1989;86(12):4505-4509.
- 403 11. Hughes AF, Freeman RB, Fadem T. The teratogenic effects of sugars on the chick embryo. *J Embryol Exp*  
404 *Morphol*. 1974;32(3):661-674.
- 405 12. Garnham EA, Beck F, Clarke CA, Stanistreet M. Effects of glucose on rat embryos in culture. *Diabetologia*.  
406 1983;25(3):291-295.
- 407 13. Ludvigsson JF, Neovius M, Söderling J, et al. Periconception glycaemic control in women with type 1 diabetes  
408 and risk of major birth defects: population based cohort study in Sweden. *BMJ*. 2018;362:k2638.
- 409 14. Persson M, Razaz N, Edstedt Bonamy A-K, Villamor E, Cnattingius S. Maternal Overweight and Obesity and Risk  
410 of Congenital Heart Defects. *J Am Coll Cardiol*. 2019;73(1):44-53.
- 411 15. Brite J, Laughon SK, Troendle J, Mills J. Maternal overweight and obesity and risk of congenital heart defects in  
412 offspring. *Int J Obes 2005*. 2014;38(6):878-882.
- 413 16. Øyen N, Diaz LJ, Leirgul E, et al. Prepregnancy Diabetes and Offspring Risk of Congenital Heart Disease: A  
414 Nationwide Cohort Study. *Circulation*. 2016;133(23):2243-2253.
- 415 17. Hoang TT, Marengo LK, Mitchell LE, Canfield MA, Agopian AJ. Original Findings and Updated Meta-Analysis for  
416 the Association Between Maternal Diabetes and Risk for Congenital Heart Disease Phenotypes. *Am J Epidemiol*.  
417 2017;186(1):118-128.
- 418 18. Leirgul E, Brodwall K, Greve G, et al. Maternal Diabetes, Birth Weight, and Neonatal Risk of Congenital Heart  
419 Defects in Norway, 1994-2009. *Obstet Gynecol*. 2016;128(5):1116-1125.
- 420 19. Liu S, Joseph KS, Lisonkova S, et al. Association between maternal chronic conditions and congenital heart  
421 defects: a population-based cohort study. *Circulation*. 2013;128(6):583-589.

- 422 20. Fisher SC, Van Zutphen AR, Werler MM, et al. Maternal Antihypertensive Medication Use and Congenital Heart  
423 Defects: Updated Results From the National Birth Defects Prevention Study. *Hypertens Dallas Tex* 1979.  
424 2017;69(5):798-805.
- 425 21. Boyd HA, Basit S, Behrens I, et al. Association Between Fetal Congenital Heart Defects and Maternal Risk of  
426 Hypertensive Disorders of Pregnancy in the Same Pregnancy and Across Pregnancies. *Circulation*.  
427 2017;136(1):39-48.
- 428 22. Auger N, Fraser WD, Healy-Profítós J, Arbour L. Association Between Preeclampsia and Congenital Heart  
429 Defects. *JAMA*. 2015;314(15):1588-1598.
- 430 23. Cornier M-A, Dabelea D, Hernandez TL, et al. The metabolic syndrome. *Endocr Rev*. 2008;29(7):777-822.
- 431 24. Jeyabalan A, Hubel CA, Roberts JM. Metabolic Syndrome and Preeclampsia. In: Taylor RN, Roberts JM,  
432 Cunningham FG, Lindheimer MD, eds. *Chesley's Hypertensive Disorders in Pregnancy*. 4<sup>th</sup> ed. Academic Press;  
433 2015:133-160.
- 434 25. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.  
435 *Obes Rev Off J Int Assoc Study Obes*. 2015;16(1):1-12.
- 436 26. Grieger JA, Bianco-Miotto T, Grzeskowiak LE, et al. Metabolic syndrome in pregnancy and risk for adverse  
437 pregnancy outcomes: A prospective cohort of nulliparous women. *PLoS Med*. 2018;15(12):e1002710.
- 438 27. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes*. 1988;37(12):1595-  
439 1607.
- 440 28. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.  
441 Available from: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed December 18, 2019.
- 442 29. Block SR, Watkins SM, Salemi JL, et al. Maternal pre-pregnancy body mass index and risk of selected birth  
443 defects: evidence of a dose-response relationship. *Paediatr Perinat Epidemiol*. 2013;27(6):521-531.

- 444 30. Blomberg MI, Källén B. Maternal obesity and morbid obesity: the risk for birth defects in the offspring. *Birt*  
445 *Defects Res A Clin Mol Teratol.* 2010;88(1):35-40.
- 446 31. Gilboa SM, Correa A, Botto LD, et al. Association between prepregnancy body mass index and congenital heart  
447 defects. *Am J Obstet Gynecol.* 2010;202(1):51.e1-51.e10.
- 448 32. Mills JL, Troendle J, Conley MR, Carter T, Druschel CM. Maternal obesity and congenital heart defects: a  
449 population-based study. *Am J Clin Nutr.* 2010;91(6):1543-1549.
- 450 33. Rankin J, Tennant PWG, Stothard KJ, Bythell M, Summerbell CD, Bell R. Maternal body mass index and  
451 congenital anomaly risk: a cohort study. *Int J Obes 2005.* 2010;34(9):1371-1380.
- 452 34. Shaw GM, Carmichael SL. Prepregnant obesity and risks of selected birth defects in offspring. *Epidemiol Camb*  
453 *Mass.* 2008;19(4):616-620.
- 454 35. Cedergren MI, Källén BAJ. Maternal obesity and infant heart defects. *Obes Res.* 2003;11(9):1065-1071.
- 455 36. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal Obesity and Risk for Birth Defects.  
456 *Pediatrics.* 2003;111(Supplement 1):1152-1158.
- 457 37. Watkins ML, Botto LD. Maternal prepregnancy weight and congenital heart defects in offspring. *Epidemiol Camb*  
458 *Mass.* 2001;12(4):439-446.
- 459 38. Shaw GM, Todoroff K, Schaffer DM, Selvin S. Maternal height and prepregnancy body mass index as risk factors  
460 for selected congenital anomalies. *Paediatr Perinat Epidemiol.* 2000;14(3):234-239.
- 461 39. Liu X, Liu G, Wang P, et al. Prevalence of congenital heart disease and its related risk indicators among 90,796  
462 Chinese infants aged less than 6 months in Tianjin. *Int J Epidemiol.* 2015;44(3):884-893.
- 463 40. Agopian AJ, Moulik M, Gupta-Malhotra M, Marengo LK, Mitchell LE. Descriptive epidemiology of non-syndromic  
464 complete atrioventricular canal defects. *Paediatr Perinat Epidemiol.* 2012;26(6):515-524.

- 465 41. Vereczkey A, Gerencsér B, Czeizel AE, Szabó I. Association of certain chronic maternal diseases with the risk of  
466 specific congenital heart defects: a population-based study. *Eur J Obstet Gynecol Reprod Biol.* 2014;182:1-6.
- 467 42. Kovalenko AA, Anda EE, Odland JØ, Nieboer E, Brenn T, Krettek A. Risk Factors for Ventricular Septal Defects in  
468 Murmansk County, Russia: A Registry-Based Study. *Int J Environ Res Public Health.* 2018;15(7):1320.
- 469 43. Vinceti M, Malagoli C, Rothman KJ, et al. Risk of birth defects associated with maternal pregestational diabetes.  
470 *Eur J Epidemiol.* 2014;29(6):411-418.
- 471 44. Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. *Am J Obstet Gynecol.*  
472 2008;199(3):237.e1-9.
- 473 45. Erickson JD. Risk factors for birth defects: data from the Atlanta Birth Defects Case-Control Study. *Teratology.*  
474 1991;43(1):41-51.
- 475 46. Chou H-H, Chiou M-J, Liang F-W, Chen L-H, Lu T-H, Li C-Y. Association of maternal chronic disease with risk of  
476 congenital heart disease in offspring. *CMAJ Can Med Assoc J J Assoc Medicale Can.* 2016;188(17-18):E438-E446.
- 477 47. Sharpe PB, Chan A, Haan EA, Hiller JE. Maternal diabetes and congenital anomalies in South Australia 1986-  
478 2000: a population-based cohort study. *Birt Defects Res A Clin Mol Teratol.* 2005;73(9):605-611.
- 479 48. Brodwall K, Leirgul E, Greve G, et al. Possible Common Aetiology behind Maternal Preeclampsia and Congenital  
480 Heart Defects in the Child: a Cardiovascular Diseases in Norway Project Study. *Paediatr Perinat Epidemiol.*  
481 2016;30(1):76-85.
- 482 49. Liu S, Rouleau J, León JA, Sauve R, Joseph KS, Ray JG. Impact of pre-pregnancy diabetes mellitus on congenital  
483 anomalies, Canada, 2002-2012. *Health Promot Chronic Dis Prev Can Res Policy Pract.* 2015;35(5):79-84.
- 484 50. Denison FC, Aedla NR, Keag O, et al. Care of Women with Obesity in Pregnancy: Green-top Guideline No. 72.  
485 *BJOG Int J Obstet Gynaecol.* 2019;126(3):e62-e106.
- 486 51. Helle E, Priest JR. Maternal Obesity and Diabetes Mellitus as Risk Factors for Congenital Heart Disease in the  
487 Offspring. *J Am Heart Assoc.* 2020;9(8):e011541.

- 488 52. Basu M, Zhu J-Y, LaHaye S, et al. Epigenetic mechanisms underlying maternal diabetes-associated risk of  
489 congenital heart disease. *JCI Insight*. 2017;2(20):e95085.
- 490 53. Suzuki N, Svensson K, Eriksson UJ. High glucose concentration inhibits migration of rat cranial neural crest cells  
491 in vitro. *Diabetologia*. 1996;39(4):401-411.
- 492 54. Wang X-Y, Li S, Wang G, et al. High glucose environment inhibits cranial neural crest survival by activating  
493 excessive autophagy in the chick embryo. *Sci Rep*. 2015;5:18321.
- 494 55. Kumar SD, Vijaya M, Samy RP, et al. Zinc supplementation prevents cardiomyocyte apoptosis and congenital  
495 heart defects in embryos of diabetic mice. *Free Radic Biol Med*. 2012;53(8):1595-1606.
- 496 56. Wang F, Fisher SA, Zhong J, Wu Y, Yang P. Superoxide Dismutase 1 In Vivo Ameliorates Maternal Diabetes  
497 Mellitus-Induced Apoptosis and Heart Defects Through Restoration of Impaired Wnt Signaling. *Circ Cardiovasc*  
498 *Genet*. 2015;8(5):665-676.
- 499 57. Engineer A, Saiyin T, Lu X, et al. Sapropterin Treatment Prevents Congenital Heart Defects Induced by  
500 Pregestational Diabetes Mellitus in Mice. *J Am Heart Assoc*. 2018;7(21):e009624.
- 501 58. Wang G, Huang W, Cui S, et al. Autophagy is involved in high glucose-induced heart tube malformation. *Cell*  
502 *Cycle Georget Tex*. 2015;14(5):772-783.
- 503 59. Reaven GM. Insulin resistance: from bit player to centre stage. *CMAJ Can Med Assoc J J Assoc Medicale Can*.  
504 2011;183(5):536-537.
- 505 60. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. *Lancet Lond Engl*.  
506 2016;387(10022):999-1011.
- 507 61. WHO. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Available from:  
508 [https://www.who.int/diabetes/publications/Hyperglycaemia\\_In\\_Pregnancy/en/](https://www.who.int/diabetes/publications/Hyperglycaemia_In_Pregnancy/en/). Accessed July 28, 2020.
- 509 62. National Institute for Health and Care Excellence. 2018 Surveillance of Diabetes in Pregnancy: Management  
510 from Preconception to the Postnatal Period (NICE Guideline NG3). Available from:

- 511 <https://www.nice.org.uk/guidance/ng3>. Published February 25, 2015. Updated August 26, 2015. Accessed May  
512 3, 2020.
- 513 63. von Versen-Hoeynck FM, Powers RW. Maternal-fetal metabolism in normal pregnancy and preeclampsia. *Front*  
514 *Biosci J Virtual Libr.* 2007;12:2457-2470.
- 515 64. Pihl K, Larsen T, Krebs L, Christiansen M. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in  
516 prediction of small-for-gestational-age fetuses. *Prenat Diagn.* 2008;28(12):1131-1135.
- 517 65. Pihl K, Larsen T, Laursen I, Krebs L, Christiansen M. First trimester maternal serum pregnancy-specific beta-1-  
518 glycoprotein (SP1) as a marker of adverse pregnancy outcome. *Prenat Diagn.* 2009;29(13):1256-1261.
- 519 66. De Villiers CP, Hedley PL, Placing S, et al. Placental protein-13 (PP13) in combination with PAPP-A and free leptin  
520 index (fLI) in first trimester maternal serum screening for severe and early preeclampsia. *Clin Chem Lab Med.*  
521 2017;56(1):65-74.
- 522 67. Thagaard IN, Krebs L, Holm J-C, Lange T, Larsen T, Christiansen M. Adiponectin and leptin as first trimester  
523 markers for gestational diabetes mellitus: a cohort study. *Clin Chem Lab Med.* 2017;55(11):1805-1812.
- 524 68. Hedley PL, Placing S, Wøjdemann K, et al. Free leptin index and PAPP-A: a first trimester maternal serum  
525 screening test for pre-eclampsia. *Prenat Diagn.* 2010;30(2):103-109.
- 526 69. Godfrey KM, Barker DJ. Fetal programming and adult health. *Public Health Nutr.* 2001;4(2B):611-624.
- 527 70. de Jong J, Garne E, Wender-Ozegowska E, Morgan M, de Jong-van den Berg LTW, Wang H. Insulin analogues in  
528 pregnancy and specific congenital anomalies: a literature review. *Diabetes Metab Res Rev.* 2016;32(4):366-375.
- 529 71. Given JE, Loane M, Garne E, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific  
530 congenital anomalies: exploratory case-control study. *BMJ.* 2018;361:k2477.
- 531 72. Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal Hypertension During Pregnancy and the Risk of  
532 Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis. *Pediatr Cardiol.* 2015;36(7):1442-  
533 1451.

- 534 73. Zheng Z, Yang T, Chen L, et al. Increased maternal Body Mass Index is associated with congenital heart defects:  
535 An updated meta-analysis of observational studies. *Int J Cardiol.* 2018;273:112-120.
- 536 74. Liu X, Ding G, Yang W, et al. Maternal Body Mass Index and Risk of Congenital Heart Defects in Infants: A Dose-  
537 Response Meta-Analysis. *BioMed Res Int.* 2019;2019:1315796.
- 538 75. Berglind D, Willmer M, Näslund E, Tynelius P, Sørensen TIA, Rasmussen F. Differences in gestational weight gain  
539 between pregnancies before and after maternal bariatric surgery correlate with differences in birth weight but  
540 not with scores on the body mass index in early childhood. *Pediatr Obes.* 2014;9(6):427-434.
- 541 76. Willmer M, Berglind D, Sørensen TIA, Näslund E, Tynelius P, Rasmussen F. Surgically induced interpregnancy  
542 weight loss and prevalence of overweight and obesity in offspring. *PLoS One.* 2013;8(12):e82247.
- 543 77. Best KE, Tennant PWG, Bell R, Rankin J. Impact of maternal body mass index on the antenatal detection of  
544 congenital anomalies. *BJOG Int J Obstet Gynaecol.* 2012;119(12):1503-1511.
- 545 78. Herskind AM, Almind Pedersen D, Christensen K. Increased prevalence of congenital heart defects in  
546 monozygotic and dizygotic twins. *Circulation.* 2013;128(11):1182-1188.
- 547 79. Pober BR. Williams-Beuren syndrome. *N Engl J Med.* 2010;362(3):239-252.
- 548 80. Forsythe E, Beales PL. Bardet-Biedl syndrome. *Eur J Hum Genet EJHG.* 2013;21(1):8-13.
- 549 81. WHO. Obesity and overweight. Available from: [https://www.who.int/news-room/fact-sheets/detail/obesity-](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)  
550 [and-overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight). Published April 1, 2020. Accessed May 3, 2020.
- 551 82. Centers for Disease Control and Prevention. Prevalence of Obesity and Severe Obesity Among Adults: United  
552 States, 2017–2018. Available from: <https://www.cdc.gov/nchs/products/databriefs/db360.htm>. Published  
553 February 2020. Accessed June 24, 2020.
- 554 83. Poston L, Caleyachetty R, Cnattingius S, et al. Preconceptional and maternal obesity: epidemiology and health  
555 consequences. *Lancet Diabetes Endocrinol.* 2016;4(12):1025-1036.

- 556 84. Baumfeld Y, Novack L, Wiznitzer A, et al. Pre-Conception Dyslipidemia Is Associated with Development of  
557 Preeclampsia and Gestational Diabetes Mellitus. *PLoS One*. 2015;10(10):e0139164.
- 558 85. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in  
559 later life: systematic review and meta-analysis. *BMJ*. 2007;335(7627):974.
- 560 86. Alonso-Ventura V, Li Y, Pasupuleti V, Roman YM, Hernandez AV, Pérez-López FR. Effects of preeclampsia and  
561 eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis.  
562 *Metabolism*. 2020;102:154012.

563

564 **Table and Figure Legends**

565 **FIGURE 1.** Flow diagram

566 The process of selection of studies that were included in the review. Literature search included studies published from  
567 January 1, 1990 to October 6, 2019.

568 Abbreviations: CHDs, congenital heart defects; ICD, International Classification of Disease; NOS, Newcastle-Ottawa  
569 Scale

570

571 **FIGURE 2.** Maternal metabolic disorders and risk of any congenital heart defect in the offspring.

572 Any CHDs defined as the whole group of heart defects (only including studies that explicitly listed their definition  
573 thereof). Obesity is defined as BMI  $\geq 30$  kg/m<sup>2</sup> unless other is stated; early-onset PE defined as diagnosed before  
574 gestational week 34; and PGDM are defined as DM1 or DM2. All risk estimates are adjusted unless other is stated; \*,  
575 not adjusted; §, isolated defects; ¶, obesity defined from ICD-10 codes; £, BMI  $\geq 35$  kg/m<sup>2</sup>; ¥, BMI  $\geq 28$  kg/m<sup>2</sup>; †, BMI  
576 35-40 kg/m<sup>2</sup>; #, untreated hypertension; ‡, estimate only for severe CHDs; @, results from singleton pregnancies.

577 Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,  
578 odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

579

580 **TABLE 1.** Summary table of characteristics of included studies

581 See Table S3 for further details. Details on NOS score can be seen in Table S2.

582 Abbreviations: DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; PE, preeclampsia; PGDM,  
583 pregestational diabetes

584

Any congenital heart defect

Study

Obesity

|                        |    |      |
|------------------------|----|------|
| Brite et al. [15]      | OR | 1.26 |
| Gilboa et al. [31] §   | OR | 1.31 |
| Liu et al. [19] α      | OR | 1.48 |
| Wills et al. [32]      | OR | 1.16 |
| Watkins et al. [37] §€ | OR | 1.15 |
|                        | OR | 1.29 |
| Persson et al. [14] †  | PR | 1.37 |

PGDM

|                      |    |      |
|----------------------|----|------|
| Correa et al. [44] § | OR | 4.64 |
| Leirgul et al. [18]  | RR | 2.92 |
| Øyen et al. [16]     | RR | 3.96 |
| Hoang et al. [17]    | PR | 3.24 |

DM1

|                        |    |      |
|------------------------|----|------|
| Chou et al. [46]       | OR | 2.32 |
| Liu et al. [19]        | OR | 4.65 |
| Ludvigsson et al. [13] | RR | 3.19 |

DM2

|                  |    |      |
|------------------|----|------|
| Chou et al. [46] | OR | 2.85 |
| Liu et al. [19]  | OR | 4.12 |

GDM

|                      |    |      |
|----------------------|----|------|
| Correa et al. [44] § | OR | 1.59 |
| Liu et al. [39]      | OR | 1.80 |
| Leirgul et al. [18]  | RR | 1.47 |
| Hoang et al. [17]    | PR | 1.49 |

Hypertension


|                      |    |      |
|----------------------|----|------|
| Liu et al. [19]      | OR | 1.81 |
| Chou et al. [46]     | OR | 1.87 |
| Fisher et al. [20] # | OR | 1.23 |

PE (early-onset)

|                        |    |      |
|------------------------|----|------|
| Boyd et al. [21]       | OR | 7.00 |
| Brodwall et al. [48] ‡ | RR | 2.80 |
| Auger et al. [22] @    | PR | 5.53 |

Obesity+GDM

|                    |    |      |
|--------------------|----|------|
| Gilboa et al. [31] | OR | 1.82 |
|--------------------|----|------|



medRxiv preprint doi: <https://doi.org/10.1101/2020.06.25.20140186>; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Records identified from database search (PubMed and Embase)  
(n = 2 053)

Additional records identified from other sources (e.g., reference lists)  
(n = 23)

Records screened (titles and abstracts)  
(n = 2 076)

medRxiv preprint doi: <https://doi.org/10.1101/2020.06.29.20140186>; this version posted September 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1 990 records excluded

Full-text articles assessed for eligibility  
(n = 86)

50 full-text articles excluded, with reasons:

The studies were not related to our topic (n = 9)  
The studies did not report specific CHDs referable to ICD-10 codes (n = 22)  
The studies had less than 15 CHD cases available for comparison (n = 9)  
Studies without healthy controls or a non-exposed control group (n = 9)  
Studies incl. data presented elsewhere (n = 1)

Full-text articles evaluated with NOS scores  
(n = 36)

6 articles excluded due to low methodological quality, NOS < 7

Studies included in review (n = 30)

Case-control studies (n = 13)  
Cohort studies (n = 17)

| Characteristics                    | Range of values  |
|------------------------------------|--|
| Year of publication                | 1991-2019  |
| Country of study population        | North America (n=15), Europe (n=12), Other countries (n=3)   |
| Study design                       | Cohort (n=17), Case-control (n=13)   |
| Population size                    | Cohorts (41 013 - 4 207 898), Case-controls (525 - 1 124 370)  |
| Cases with CHDs                    | Cohorts (233 - 48 249), Case-controls (35 - 10 625)  |
| Included study population          | Only live births (n=15); Live births + stillbirths (n=8); Live births + stillbirths + terminated pregnancies (n=7) |
| Plurality                          | Singletons (n=13), All (n=8), Not stated (n=9)   |
| Maternal exposure                  | Obesity (n=15), PGDM (n=9), DM1 (n=4), DM2 (n=2), GDM (n=7), hypertension (n=4), PE (n=3), obesity+GDM (n=1)       |
| Sources of maternal exposure       | Registers (n=18), interviews (n=9), medical records (n=2), questionnaire+medical records (n=1)                     |
| Newcastle-Ottawa Scale (NOS) score | 7 - 8  |